Immudyne, Inc. — Form 10-Q Summary
Period: Three months ended March 31, 2017; filed July 7, 2017. The supplied filing is for Immudyne, Inc., not LifeMD, Inc.
Business context and financial results
Immudyne developed and sold yeast beta-glucan nutraceutical and cosmetic ingredients and finished skincare products. Its majority-owned subsidiary, Immudyne PR, handled digital marketing and skincare products. The statements are unaudited and consolidated.
| Metric | Q1 2017 | Q1 2016 |
|---|---|---|
| Net sales | $424,462 | $1,641,028 |
| Gross profit / margin | $221,106 / 52% | $303,086 / 18% |
| Operating expenses | $596,092 | $408,182 |
| Operating loss | $374,986 | $105,096 |
| Net loss | $1,072,535 | $108,159 |
| Net loss attributable to Immudyne | $1,044,805 | $62,049 |
| Operating cash flow | $(473,256) | $(122,155) |
| Financing cash flow | $671,751 | $92,793 |
Cash was $381,056 at quarter-end, versus $182,561 at December 31, 2016. Current assets were $1,073,702 and current liabilities $2,397,110, resulting in negative working capital of $1,323,408; the current ratio was 0.45. Current liabilities included $1,809,890 of derivative liabilities and $25,000 of notes payable, net of discount. Stockholders’ deficit was $1,323,408.
Material changes versus prior year
- Sales declined 74%. Finished cosmetic product sales fell to $167,899 from $1,375,118; additives sales were $256,563 versus $285,160.
- Management attributed lower finished-product sales partly to resources devoted to preparing a launch of licensed hair-loss products and to shifting toward internal marketing. It said additives sales were broadly consistent with expectations.
- Gross margin rose to 52% from 18%, which management attributed to a greater sales mix of higher-margin additives and lower marketing costs than in Q1 2016. Gross profit nevertheless fell 27%.
- Operating expenses increased 46%, including higher compensation, professional fees, and general and administrative costs.
- Net loss worsened substantially. Interest expense was $649,357, including debt-discount amortization and a reported $553,222 noncash adjustment for loss on settlement of notes payable in the cash-flow reconciliation. The filing’s notes describe significant losses on conversions of debt to shares and warrants.
Liquidity, outlook and risks
- Going concern: The company reported an accumulated deficit of approximately $10.7 million and negative operating cash flow, raising substantial doubt about its ability to continue as a going concern. Management said it needed higher sales and/or additional capital to meet 2017 needs; it believed existing operations and recent financing could fund operations through 2017, but gave no assurance.
- Financing and dilution: Q1 stock-and-warrant sales raised $647,944. The company also repaid or converted borrowings; its $25,000 working-capital line had no available capacity at quarter-end. Further equity or debt financing could be unavailable or dilutive, and debt could impose restrictive covenants.
- Outlook: Management expected the licensed shampoo, conditioner, and leave-in foam to contribute meaningfully to revenue during the remainder of 2017, based on initial sales, and said the internal marketing shift was intended to support long-term success. No quantified revenue or earnings guidance was provided.
- Derivative exposure: Options, warrants, and conversion instruments were classified as liabilities because the company could lack sufficient authorized shares to settle them in stock. Management planned to seek shareholder approval to increase authorized shares in Q3 2017. The liability was valued at $1,809,890 at quarter-end.
- Concentration and operating risks: One additives customer represented 59% of consolidated sales in Q1 2017 and 45% of receivables at quarter-end. Risks also included product regulation, intellectual-property protection, marketing execution, and dependence on financing.
- Controls: Management concluded disclosure controls were ineffective, citing material weaknesses involving segregation of duties, accounting policies and procedures, computer security and disaster recovery, and absence of a written whistleblower policy.
- Other items: Management reported no known legal matter expected to have a material adverse effect. A subsequent April 2017 transaction issued 217,390 shares and 108,696 warrants in connection with a $50,000 payment obligation under the Pilaris product-license agreement.
Important facts for investors to verify
- Confirm the issuer and reporting entity: this filing identifies Immudyne, Inc., despite the request metadata naming LifeMD, Inc.
- Track sales after the hair-care launch, especially finished-product revenue, customer concentration, and the economics of the internal marketing strategy.
- Review cash burn, financing availability, and progress toward resolving the company’s going-concern uncertainty.
- Assess the potential dilution and cash-settlement exposure from outstanding options, warrants, and derivative liabilities, including whether authorized-share increases were approved.
- Monitor remediation of the disclosed control weaknesses and verify the accounting for debt-conversion losses and related noncash charges.